Scribe Therapeutics is preparing to take its first cardiometabolic programme into the clinic in mid-2026, positioning STX-1150 as a potentially...
California-based gene-editing company Scribe Therapeutics recently unveiled its plans to develop the most advanced platform for breakthrough...
